Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. more
Time Frame | TPST | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.85% | -2.82% | 0.15% |
1-Month Return | -22.72% | -4.22% | 1.78% |
3-Month Return | -37.25% | -9.52% | 8.7% |
6-Month Return | -72.99% | -3.45% | 12.24% |
1-Year Return | -75.67% | 5.62% | 30.9% |
3-Year Return | -88.74% | 3.8% | 30.19% |
5-Year Return | -99.11% | 39.68% | 91.72% |
10-Year Return | -99.99% | 105.02% | 203.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 1.05M | 815.00K | 1.27M | 1.81M | 381.00K | [{"date":"2019-12-31","value":57.99,"profit":true},{"date":"2020-12-31","value":44.93,"profit":true},{"date":"2021-12-31","value":70.01,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":21,"profit":true}] |
Gross Profit | (1.05M) | (815.00K) | (1.27M) | (1.81M) | (381.00K) | [{"date":"2019-12-31","value":-105200000,"profit":false},{"date":"2020-12-31","value":-81500000,"profit":false},{"date":"2021-12-31","value":-127000000,"profit":false},{"date":"2022-12-31","value":-181400000,"profit":false},{"date":"2023-12-31","value":-38100000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 44.35M | 19.30M | 26.99M | 34.64M | 29.16M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":43.52,"profit":true},{"date":"2021-12-31","value":60.85,"profit":true},{"date":"2022-12-31","value":78.11,"profit":true},{"date":"2023-12-31","value":65.75,"profit":true}] |
Operating Income | (45.40M) | (19.30M) | (26.99M) | (34.64M) | (29.16M) | [{"date":"2019-12-31","value":-4539900000,"profit":false},{"date":"2020-12-31","value":-1929800000,"profit":false},{"date":"2021-12-31","value":-2698600000,"profit":false},{"date":"2022-12-31","value":-3464000000,"profit":false},{"date":"2023-12-31","value":-2915700000,"profit":false}] |
Total Non-Operating Income/Expense | - | 180.00K | (2.60M) | (2.69M) | (1.84M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1443.33,"profit":false},{"date":"2022-12-31","value":-1492.78,"profit":false},{"date":"2023-12-31","value":-1021.11,"profit":false}] |
Pre-Tax Income | (44.57M) | (19.21M) | (28.30M) | (35.71M) | (29.49M) | [{"date":"2019-12-31","value":-4456800000,"profit":false},{"date":"2020-12-31","value":-1920800000,"profit":false},{"date":"2021-12-31","value":-2830200000,"profit":false},{"date":"2022-12-31","value":-3570900000,"profit":false},{"date":"2023-12-31","value":-2949100000,"profit":false}] |
Income Taxes | 1.00K | (90.00K) | 1.25M | 1.07M | - | [{"date":"2019-12-31","value":0.08,"profit":true},{"date":"2020-12-31","value":-7.21,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":85.66,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | - | (19.12M) | (29.55M) | (36.78M) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1911800000,"profit":false},{"date":"2021-12-31","value":-2955000000,"profit":false},{"date":"2022-12-31","value":-3677800000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | - | (19.21M) | (28.30M) | (35.71M) | (31.11M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1920800000,"profit":false},{"date":"2021-12-31","value":-2830200000,"profit":false},{"date":"2022-12-31","value":-3570900000,"profit":false},{"date":"2023-12-31","value":-3110600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (44.57M) | (19.12M) | (29.55M) | (36.78M) | (29.49M) | [{"date":"2019-12-31","value":-4456800000,"profit":false},{"date":"2020-12-31","value":-1911800000,"profit":false},{"date":"2021-12-31","value":-2955000000,"profit":false},{"date":"2022-12-31","value":-3677800000,"profit":false},{"date":"2023-12-31","value":-2949100000,"profit":false}] |
EPS (Diluted) | (48.90) | (29.10) | (16.56) | (3.26) | (1.95) | [{"date":"2019-12-31","value":-4890,"profit":false},{"date":"2020-12-31","value":-2910,"profit":false},{"date":"2021-12-31","value":-1656,"profit":false},{"date":"2022-12-31","value":-326,"profit":false},{"date":"2023-12-31","value":-195,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TPST | |
---|---|
Cash Ratio | 1.58 |
Current Ratio | 1.69 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TPST | |
---|---|
ROA (LTM) | -54.28% |
ROE (LTM) | -289.26% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TPST | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.66 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.34 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TPST | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 3.37 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.31 |
Tempest Therapeutics Inc (TPST) share price today is $0.8346
Yes, Indians can buy shares of Tempest Therapeutics Inc (TPST) on Vested. To buy Tempest Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TPST stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Tempest Therapeutics Inc (TPST) via the Vested app. You can start investing in Tempest Therapeutics Inc (TPST) with a minimum investment of $1.
You can invest in shares of Tempest Therapeutics Inc (TPST) via Vested in three simple steps:
The 52-week high price of Tempest Therapeutics Inc (TPST) is $6. The 52-week low price of Tempest Therapeutics Inc (TPST) is $0.8.
The price-to-earnings (P/E) ratio of Tempest Therapeutics Inc (TPST) is
The price-to-book (P/B) ratio of Tempest Therapeutics Inc (TPST) is 3.37
The dividend yield of Tempest Therapeutics Inc (TPST) is 0.00%
The market capitalization of Tempest Therapeutics Inc (TPST) is $39.92M
The stock symbol (or ticker) of Tempest Therapeutics Inc is TPST